The role of bactericidal/permeability-increasing protein in the treatment of primate bacteremia and septic shock. (Q54638238)

1 June 2018

title

The role of bactericidal/permeability-increasing protein in the treatment of primate bacteremia and septic shock. (English)

1 reference

1 June 2018

1 reference

6

1 reference

1 June 2018

author name string

M A Rogy

1

1 reference

1 June 2018

H S Oldenburg

2

1 reference

1 June 2018

S E Calvano

3

1 reference

1 June 2018

W J Montegut

4

1 reference

1 June 2018

S A Stackpole

5

1 reference

1 June 2018

M N Marra

7

1 reference

1 June 2018

R W Scott

8

1 reference

1 June 2018

J J Seilhammer

9

1 reference

1 June 2018

L L Moldawer

10

1 reference

1 June 2018

publication date

1 March 1994

1 reference

1 June 2018

Journal of Clinical Immunology

published in

1 reference

1 June 2018

volume

14

1 reference

1 June 2018

issue

2

1 reference

1 June 2018

page(s)

120-133

1 reference

1 June 2018

Cytokine appearance in human endotoxemia and primate bacteremia

cites work

1 reference

12 December 2020

A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes.

1 reference

12 December 2020

The metabolic effects of platelet-activating factor antagonism in endotoxemic man

1 reference

12 December 2020

Recombinant soluble tumor necrosis factor receptor proteins protect mice from lipopolysaccharide-induced lethality

1 reference

12 December 2020

The role of bactericidal/permeability-increasing protein as a natural inhibitor of bacterial endotoxin

1 reference

12 December 2020

Endotoxemia elicits increased circulating beta 2-IFN/IL-6 in man

1 reference

12 December 2020

Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia

1 reference

12 December 2020

Separation of sublethal and lethal effects of polymorphonuclear leukocytes on Escherichia coli

1 reference

12 December 2020

Persistently elevated soluble tumor necrosis factor receptor and interleukin-1 receptor antagonist levels in critically ill patients

1 reference

12 December 2020

Endotoxic lipid A interaction with human platelets. Structure-function analysis of lipid A homologs obtained from Salmonella minnesota Re595 lipopolysaccharide

1 reference

12 December 2020

Macrophages rapidly internalize their tumor necrosis factor receptors in response to bacterial lipopolysaccharide

1 reference

12 December 2020

Endotoxin-neutralizing properties of the 25 kD N-terminal fragment and a newly isolated 30 kD C-terminal fragment of the 55-60 kD bactericidal/permeability-increasing protein of human neutrophils.

1 reference

12 December 2020

Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease

1 reference

12 December 2020

Identification of a lipid A binding site in the acute phase reactant lipopolysaccharide binding protein.

1 reference

12 December 2020

Endotoxemia after burn injury: effect of early excision on circulating endotoxin levels

1 reference

12 December 2020

Are plasma endotoxin levels related to burn size and prognosis?

1 reference

12 December 2020

Prostaglandin E production by human blood monocytes and mouse peritoneal macrophages

1 reference

12 December 2020

Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo

1 reference

12 December 2020

Cationic antimicrobial proteins isolated from human neutrophil granulocytes in the presence of diisopropyl fluorophosphate

1 reference

12 December 2020

Endotoxins and disease mechanisms

1 reference

12 December 2020

A controlled trial of HA-1A in a canine model of gram-negative septic shock.

1 reference

12 December 2020

Bactericidal/permeability-increasing protein has endotoxin-neutralizing activity

1 reference

12 December 2020

Interleukin-1 receptor antagonist circulates in experimental inflammation and in human disease.

1 reference

12 December 2020

Shedding of tumor necrosis factor receptors by activated human neutrophils

1 reference

12 December 2020

Endotoxin stimulates bronchial epithelial cells to release chemotactic factors for neutrophils. A potential mechanism for neutrophil recruitment, cytotoxicity, and inhibition of proliferation in bronchial inflammation

1 reference

12 December 2020

Lipopolysaccharide antagonists

1 reference

12 December 2020

Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group

1 reference

12 December 2020

Recognition of an endothelial determinant for CD 18-dependent human neutrophil adherence and transendothelial migration

1 reference

12 December 2020

Responses of baboons to traditionally pyrogenic agents

1 reference

12 December 2020

A family of lipopolysaccharide binding proteins involved in responses to gram-negative sepsis.

1 reference

12 December 2020

Structure and function of lipopolysaccharide binding protein

1 reference

12 December 2020

Human bactericidal/permeability-increasing protein and a recombinant NH2-terminal fragment cause killing of serum-resistant gram-negative bacteria in whole blood and inhibit tumor necrosis factor release induced by the bacteria

1 reference

12 December 2020

Quantitative measurement of endotoxin in canine plasma using the new endotoxin-specific chromogenic test

1 reference

12 December 2020

Shock and tissue injury induced by recombinant human cachectin

1 reference

12 December 2020

Cultured human vascular endothelial cells acquire adhesiveness for neutrophils after stimulation with interleukin 1, endotoxin, and tumor-promoting phorbol diesters

1 reference

12 December 2020

Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia

1 reference

12 December 2020

Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group

1 reference

12 December 2020

Assessment of ability of murine and human anti-lipid A monoclonal antibodies to bind and neutralize lipopolysaccharide

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF01541345

1 reference

1 June 2018

1 reference

1 June 2018